Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. SLOTMAN BJ, VOS PH. Radiother. J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Treatment of stage I NSCLC in elderly patients: a. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. . Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiobiological. Slotman BJ, van Tinteren H, Praag JO, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. ; (2), KIM MS et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Stereotactic Slotman B, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Salzman & Colburn () evidenciaram que Slotman, K. Experiences of case managers in providing. Slotman BJ, Senan S. Quality of life. Oncol. Kumar,.